Vector Borne Diseases: Clinical Trials

368 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

368 completed. 368 Phase 2, 79 Phase 1, 47 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2368Completed 368
Phase 179Completed 79
Phase 347Completed 47

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 368 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria
Phase 2CompletedNovartis Pharmaceuticals952025-10-102026-09-10
L9LS in Women of Childbearing Potential in Mali
Single dose of 1800 mg L9LS SC, Placebo - Malaria
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2792025-07-222026-10-30
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease
Phase 1 / Phase 2CompletedSK Bioscience Co., Ltd.1612025-02-242026-09-11
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
TDV, Placebo - Dengue Fever
Phase 2 / Phase 3CompletedTakeda1872025-01-312025-12-30
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg - DENV-3 Controlled Human Infection Model
Phase 2CompletedAbViro LLC852025-01-072026-03-31
Study to Examine the Effects of Oral Fenretinide
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue
Phase 2CompletedIsland Pharmaceuticals152024-09-052025-10-24
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
TB31F, Normal saline - Malaria,Falciparum
Phase 1 / Phase 2CompletedRadboud University Medical Center1672024-07-122026-01-22
Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients
CPLE, Placebo - Dengue Fever
Phase 1 / Phase 2CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh1842024-06-012025-04-25
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
INE963 - Uncomplicated Plasmodium Falciparum Malaria
Phase 2CompletedNovartis Pharmaceuticals522024-01-232025-11-19
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria
Phase 2CompletedNovartis Pharmaceuticals602024-01-232026-05-07
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
VLA1553 full dose, VLA1553 half dose, Control - Chikungunya Virus Infection
Phase 2CompletedValneva Austria GmbH3042023-12-182026-08-13
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection
Phase 2CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1922023-11-282026-02-06
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
BNT165c, BNT165d, Placebo - Malaria
Phase 1 / Phase 2CompletedBioNTech SE1632023-11-132026-08-28
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum
Phase 1 / Phase 2CompletedUniversity of Oxford412023-08-182026-07-20
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
mRNA-1975, mRNA-1982, Placebo - Lyme Disease
Phase 1 / Phase 2CompletedModernaTX, Inc.8072023-07-262026-07-30
L9LS MAb in Malian Adults
L9LS (VRC-MALMAB0114-00-AB), Placebo - Plasmodium Falciparum Infection, Malaria
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4902023-05-252025-04-02
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine - Uncomplicated Plasmodium Falciparum Malaria
Phase 2 / Phase 3CompletedMuhimbili University of Health and Allied Sciences3842023-05-012026-09-23
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M - Malaria,Falciparum
Phase 1 / Phase 2CompletedUniversity of Oxford3902023-04-032026-10-21
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
M5717 330 mg, M5717 500 mg, M5717 660 mg - Acute Malaria
Phase 2CompletedMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany382023-03-292025-08-27
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
V181, Butantan - DV - Dengue
Phase 2CompletedButantan Institute13642023-02-152025-11-18

Showing 20 of 368. Sign in to see all of them.

Narrower conditions

Malaria (141)  ·  Malaria, Falciparum (78)  ·  Dengue (43)  ·  Leishmaniasis, Cutaneous (28)  ·  Severe Dengue (20)  ·  Leishmaniasis (18)  ·  Malaria, Vivax (17)  ·  Encephalitis, Japanese (12)  ·  Schistosomiasis (10)  ·  Chikungunya Fever (8)  ·  Encephalitis, Tick-Borne (8)  ·  Lyme Disease (8)  ·  Chagas Disease (7)  ·  Leishmaniasis, Mucocutaneous (7)  ·  Trypanosomiasis, African (7)

Broader conditions

Infections (363)  ·  Mosquito-Borne Diseases (268)  ·  Parasitic Diseases (258)  ·  Protozoan Infections (241)  ·  RNA Virus Infections (84)  ·  Arbovirus Infections (83)  ·  Virus Diseases (83)  ·  Flaviviridae Infections (70)  ·  Flavivirus Infections (70)  ·  Euglenozoa Infections (56)  ·  Hemorrhagic Fevers, Viral (50)  ·  Malaria (45)  ·  Skin Diseases, Infectious (38)  ·  Skin and Connective Tissue Diseases (38)

Interventions

Artemether, Lumefantrine Drug Combination (18)  ·  Primaquine (17)  ·  Amodiaquine (14)  ·  miltefosine (14)  ·  Artesunate (13)  ·  fanasil, pyrimethamine drug combination (13)  ·  Chloroquine (12)  ·  Azithromycin (9)  ·  Ivermectin (9)  ·  Saline Solution (9)  ·  Sodium Chloride (9)  ·  Vaccines (8)  ·  Praziquantel (7)  ·  RTS malaria vaccine (7)  ·  Rabies Vaccines (7)

Sponsors

U.S. Army Medical Research and Development Command (36)  ·  University of Oxford (32)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (21)  ·  GlaxoSmithKline (20)  ·  London School of Hygiene and Tropical Medicine (20)  ·  Sanofi Pasteur, a Sanofi Company (17)  ·  Pfizer (13)  ·  Medicines for Malaria Venture (11)  ·  Drugs for Neglected Diseases (10)  ·  Novartis Pharmaceuticals (10)  ·  Sanofi (9)  ·  Heidelberg University (5)  ·  Hospital Universitário Professor Edgard Santos (5)  ·  Oswaldo Cruz Foundation (5)  ·  Sanaria Inc. (5)

Countries

United States (63)  ·  Mali (26)  ·  Burkina Faso (25)  ·  Kenya (23)  ·  Thailand (23)  ·  Brazil (21)  ·  United Kingdom (21)  ·  Uganda (18)  ·  Gabon (17)  ·  Colombia (15)  ·  India (13)  ·  Ghana (11)  ·  Democratic Republic of the Congo (10)  ·  Vietnam (10)  ·  Mozambique (9)

Top investigators

Adrian VS Hill, D.Phil, FRCP (4)  ·  Kassoum Kayentao, MD, MPH, PhD (4)  ·  Adrian V S Hill, MD (3)  ·  Brian Greenwood, FRCP, FRS (3)  ·  James McCarthy, Prof (3)  ·  Peter Crompton, MD, MPH (3)  ·  Adrian V Hill, DPhill FRCP (2)

Results publications

PMID 39377226, PMID 40099800, PMID 28495354, PMID 19150418, PMID 2022660, PMID 21298114, PMID 21443960, PMID 23284726, PMID 23433102, PMID 23877689, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 26571311, PMID 26881924, PMID 27695088, PMID 31672143, PMID 32932330, PMID 33998661, PMID 35664997, PMID 36875126, PMID 38830375, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12011004, PMID 12663340, PMID 15069048, PMID 16269927, PMID 16338450, PMID 16503464, PMID 16837678, PMID 16904798, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18337339, PMID 18545693, PMID 18694333, PMID 18752443, PMID 18781879, PMID 19098989, PMID 19262754, PMID 19365567, PMID 19390585

NIH funding

2014 (5), 2016 (4), 2015 (3), 2018 (2), R01NS074409 (2), R01HD095562 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1), U01AI129783 (1), U01AI141981 (1)